Edwards Lifesciences Corporation (NYSE:EW) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Edwards Lifesciences Corporation (NYSE:EW) have been assigned a consensus rating of “Moderate Buy” from the twenty-eight analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, ten have assigned a hold recommendation, fourteen have given a buy recommendation and three have issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $91.3913.

EW has been the subject of several research analyst reports. Sanford C. Bernstein reissued a “market perform” rating and issued a $90.00 price objective on shares of Edwards Lifesciences in a report on Monday, November 3rd. UBS Group reiterated a “neutral” rating and issued a $90.00 target price on shares of Edwards Lifesciences in a research report on Monday, November 3rd. Evercore ISI boosted their price target on Edwards Lifesciences from $88.00 to $92.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Robert W. Baird set a $83.00 price objective on Edwards Lifesciences in a research note on Friday, October 31st. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, October 8th.

Insider Activity

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,020 shares of the firm’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $82.55, for a total value of $84,201.00. Following the transaction, the vice president owned 22,002 shares of the company’s stock, valued at $1,816,265.10. This trade represents a 4.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $83.08, for a total value of $1,080,040.00. Following the completion of the transaction, the chief financial officer owned 39,898 shares of the company’s stock, valued at approximately $3,314,725.84. The trade was a 24.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 1.29% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Norges Bank acquired a new position in shares of Edwards Lifesciences during the second quarter worth approximately $580,640,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in Edwards Lifesciences by 111.2% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock valued at $714,006,000 after acquiring an additional 4,805,819 shares during the period. Nuveen LLC bought a new stake in Edwards Lifesciences during the 1st quarter valued at $330,881,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Edwards Lifesciences by 278.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after acquiring an additional 4,108,270 shares during the period. Finally, Marshall Wace LLP grew its stake in shares of Edwards Lifesciences by 127.5% in the second quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock worth $539,303,000 after purchasing an additional 3,864,908 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 0.0%

EW opened at $86.74 on Friday. Edwards Lifesciences has a 12-month low of $65.94 and a 12-month high of $87.40. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The stock has a market capitalization of $50.34 billion, a PE ratio of 12.48, a P/E/G ratio of 3.97 and a beta of 1.03. The firm’s fifty day moving average price is $79.93 and its 200 day moving average price is $78.47.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.08. The company had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company’s revenue was up 14.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, research analysts expect that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.